CytoDyn Inc.·4

Mar 24, 5:23 PM ET

Ndhlovu Lishomwa C 4

4 · CytoDyn Inc. · Filed Mar 24, 2026

Research Summary

AI-generated summary of this filing

Updated

CytoDyn (CYDY) Director Ndhlovu Lishomwa C Receives 574,385-Share Award

What Happened

  • Director Ndhlovu Lishomwa C received a derivative equity award on March 20, 2026, covering 574,385 shares. The grant is reported at $0.00 (no cash paid at grant) and is an annual 2026 award approved by CytoDyn’s Compensation Committee under the company’s 2012 Equity Incentive Plan.

Key Details

  • Transaction date: 2026-03-20; Form 4 filed: 2026-03-24 (timely within the Form 4 filing window).
  • Transaction type: Award/Acquisition (derivative instrument—stock option).
  • Shares granted: 574,385; reported price at grant: $0.00.
  • Vesting: The award will vest in approximately 12 equal monthly installments beginning April 2026 through March 2027 (per footnote).
  • Plan: Award issued from shares reserved under the Issuer’s 2012 Equity Incentive Plan.
  • Shares owned after transaction: Not specified in the provided filing.

Context

  • This is a compensation grant (not an open-market purchase or sale). Such awards are common for executives and directors and do not necessarily indicate immediate buying or selling pressure — the options must vest (per schedule) before they can be exercised or sold.
  • For retail investors, outright purchases or sales by insiders typically carry clearer market signals than routine compensation grants.

Insider Transaction Report

Form 4
Period: 2026-03-20
Transactions
  • Award

    Non-qualified stock option (right to buy)

    [F1][F2]
    2026-03-20+574,385574,385 total
    Exercise: $0.28Exp: 2036-03-20Common Stock (574,385 underlying)
Footnotes (2)
  • [F1]This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").
  • [F2]The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.
Signature
/s/ Tyler Blok, Attorney-in-Fact for Lishomwa C Ndhlovu|2026-03-24

Documents

1 file
  • 4
    tm269618-6_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT